Marker Therapeutics, Inc. — Director's Dealing 2021

Feb 12, 2021

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: Marker Therapeutics, Inc. (MRKR)
CIK: 0001094038
Period of Report: 2020-12-31

Reporting Person: ELMS STEVE (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-05-19	Common Stock	A	17022	$0.00	Acquired	17022	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2000000	Indirect

Footnotes

F1: Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the
Company's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $2.35 per share, on the day immediately
preceding the date of the Company's 2019 annual meeting.

F2: The reportable securities are directly owned by Aisling Capital IV, LP ("Aisling"). The Reporting Person is a managing member of the general partner of the general partner of Aisling and may be deemed to share voting and dispositive power over the shares owned by Aisling. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein, and the inclusion of these securities herein shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purpose.